(Update: Valneva stock price)
PARIS (Agefi-Dow Jones)–Valneva shares soared 22.2%, 18.65 euros, shortly after 1:30 p.m. Thursday, when trading resumed on Euronext Paris. Trading in biotech shares had been suspended since 9:00 a.m. on Thursday, after the UK Medicines and Health Products Regulatory Agency (MHRA) announced that it had approved the French company’s Covid-19 vaccine.
The conditional marketing authorization granted by the MHRA is valid in Great Britain and Northern Ireland. It concerns the primary vaccination of adults aged 18 to 50, Valneva said in a press release.
“VLA2001 is the only inactivated whole virus Covid-19 vaccine approved in the UK and this approval could pave the way for the availability of an alternative vaccine solution for the UK population,” Valneva said.
“We believe this approval could also lead to new marketing authorizations in other regions of the world,” the group added.
The laboratory is still awaiting the green light from the European Union for its vaccine. Last month, the company said it was counting on receiving a positive opinion in April from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
-Julien Marion and Franois Schott, Agefi-Dow Jones; +33 (0)1 41 27 47 94; [email protected] ed: VLV – ECH
(Dimitri Delmond contributed this article)
Agefi-Dow Jones The financial newswire
(END) Dow Jones Newswires
April 14, 2022 07:36 ET (11:36 GMT)